XCancer

Phase 1, Single-site, Single-arm, Clinical Imaging, and Blood-based Biomarker Trial Utilizing 18F-FSPG PET to Guide Therapy in Hepatocellular Carcinoma

Description:

To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

Sponsor:

MD Anderson Cancer Center

Phase:

Phase 1

Contacts:

Simone Krebs, MD

sskrebs@mdanderson.org

(713) 563-6726

Government Study Link:

NCT07116486 - Click here to see study on

ClinicalTrials.gov

18F-FSPG

Isotope(s):
Target(s):
  • Cystine/glutamate antiporter